Corrine Savill is Chief Business Officer at Cullinan Therapeutics, Inc. (CGEM). They have made 2 open-market trades across 1 company since 2022, most recently 2025-02-19.
CIK 0001837524
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 2 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| CGEM | 240,990 | $3.1M |
Shares reported on the most recent Form 4, priced at the 2025-02-21 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| CGEM | SELL · 10b5-1 | 2024-02-01 | 2024-02-02 | $16.18 | $647K | +1.8% | +5.2% | +58.5% |
| CGEM | SELL · 10b5-1 | 2024-01-29 | 2024-01-30 | $14.09 | $564K | +29.4% | +27.8% | +87.7% |
| CGEM | SELL · 10b5-1 | 2024-01-22 | 2024-01-24 | $12.33 | $935K | +42.0% | +42.0% | +31.5% |
| CGEM | SELL | 2022-07-18 | 2022-07-21 | $15.18 | $607K | -7.3% | -15.2% | -24.2% |
| CGEM | SELL | 2022-07-11 | 2022-07-12 | $13.33 | $533K | +5.5% | -3.8% | -8.3% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.